<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01071005</url>
  </required_header>
  <id_info>
    <org_study_id>LEUBER0409</org_study_id>
    <secondary_id>Versão 03 - Emenda 1</secondary_id>
    <nct_id>NCT01071005</nct_id>
  </id_info>
  <brief_title>Pharmacodynamics of Lorelin Depot (Leuprorelin Acetate - Bergamo) Compared to Lupron Depot ® (Leuprorelin Acetate - Abbot)</brief_title>
  <official_title>Randomized Clinical Trial of the Pharmacodynamics of Lorelin Depot 3.75Mg (Leuprorelin Acetate) Produced by Laboratório Químico Farmacêutico Bergamo LTDA. Compared to Lupron Depot ® 3.75 Mg Produced by Abbott in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azidus Brasil</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azidus Brasil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to examine, in healthy subjects, the comparative&#xD;
      pharmacodynamics of Lorelin Depot (leuprorelin), manufactured by the Chemical Pharmaceutical&#xD;
      Laboratory Bergamo Ltda with the product Lupron Depot ® (leuprorelin), manufactured by Abbott&#xD;
      Laboratories Ltd, through the strength of biological markers follicle stimulating hormone&#xD;
      (FSH), luteinizing hormone (LH) and total testosterone, associated with the activity of the&#xD;
      substance.&#xD;
&#xD;
      Secondarily be observed safety (tolerability) of subjects in clinical research through the&#xD;
      comparison of clinical and laboratory parameters pre-and post-study, and incidence of adverse&#xD;
      events.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease of serum levels of luteinizing hormone, Testosterone and FSH</measure>
    <time_frame>56 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of safety through the adverse affects investigation</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lorelin Depot - Bergamo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lupron Depot® - Abbott</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorelin Depot Bergamo</intervention_name>
    <description>Lorelin Depot Bergamo, 3,75 mg, single dose.</description>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lupron Depot - Abbott</intervention_name>
    <description>Lupron Depot 3,75 mg, single dose.</description>
    <arm_group_label>comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Accept the Informed Consent.&#xD;
&#xD;
          2. Subjects of research males aged 40 to 45 years;&#xD;
&#xD;
          3. Subject of research with body mass index greater than or equal to 19 and less than or&#xD;
             equal to 30;&#xD;
&#xD;
          4. Be considered healthy, from the analysis of the clinical history and medical&#xD;
             examination;&#xD;
&#xD;
          5. Laboratory tests with results outside the values considered normal, but not considered&#xD;
             clinically relevant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have donated or lost 450 mL or more of blood in the three months preceding the study;&#xD;
&#xD;
          2. Have participated in any experimental study or have taken any experimental drug in the&#xD;
             last three months prior to the start of the study;&#xD;
&#xD;
          3. Have made regular use of medication in the last 4 weeks prior to the start of the&#xD;
             study or have made use of any medication a week before the study began;&#xD;
&#xD;
          4. Have been hospitalized for any reason, up to 8 weeks before the study;&#xD;
&#xD;
          5. Provide history of alcohol abuse, drugs or medications, or have ingested alcohol&#xD;
             within 48 hours prior to the period of hospitalization;&#xD;
&#xD;
          6. Have a history of liver disease, renal, pulmonary, gastrointestinal, hematological or&#xD;
             psychiatric;&#xD;
&#xD;
          7. Amendments pressure of any etiology requiring pharmacological treatment;&#xD;
&#xD;
          8. Present history of myocardial infarction, angina and / or heart failure.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lal Clinica Pesquisa E Desenvolvimento Ltda</name>
      <address>
        <city>Valinhos</city>
        <state>SP</state>
        <zip>13270000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>June 4, 2009</study_first_submitted>
  <study_first_submitted_qc>February 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2010</study_first_posted>
  <last_update_submitted>February 22, 2013</last_update_submitted>
  <last_update_submitted_qc>February 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2013</last_update_posted>
  <responsible_party>
    <name_title>Alexandre Frederico</name_title>
    <organization>LAL Clinica Pesquisa e Desenvolvimento Ltda</organization>
  </responsible_party>
  <keyword>Decrease serum levels of luteinizing hormone, FSH and Testosterone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

